DE69429821D1 - Farnesyl-derivate und diese enthaltende arzneimittel - Google Patents

Farnesyl-derivate und diese enthaltende arzneimittel

Info

Publication number
DE69429821D1
DE69429821D1 DE69429821T DE69429821T DE69429821D1 DE 69429821 D1 DE69429821 D1 DE 69429821D1 DE 69429821 T DE69429821 T DE 69429821T DE 69429821 T DE69429821 T DE 69429821T DE 69429821 D1 DE69429821 D1 DE 69429821D1
Authority
DE
Germany
Prior art keywords
products containing
medicinal products
farnesyl derivatives
farnesyl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429821T
Other languages
English (en)
Other versions
DE69429821T2 (de
Inventor
Yoel Kloog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of DE69429821D1 publication Critical patent/DE69429821D1/de
Publication of DE69429821T2 publication Critical patent/DE69429821T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69429821T 1993-11-12 1994-11-10 Farnesyl-derivate und diese enthaltende arzneimittel Expired - Lifetime DE69429821T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10758793A IL107587A (en) 1993-11-12 1993-11-12 Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
PCT/US1994/013345 WO1995013059A1 (en) 1993-11-12 1994-11-10 Farnesyl derivatives and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
DE69429821D1 true DE69429821D1 (de) 2002-03-21
DE69429821T2 DE69429821T2 (de) 2002-11-28

Family

ID=11065450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429821T Expired - Lifetime DE69429821T2 (de) 1993-11-12 1994-11-10 Farnesyl-derivate und diese enthaltende arzneimittel

Country Status (7)

Country Link
US (2) US5705528A (de)
EP (1) EP0729354B1 (de)
AU (1) AU1396395A (de)
CA (1) CA2176373C (de)
DE (1) DE69429821T2 (de)
IL (1) IL107587A (de)
WO (1) WO1995013059A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
DE69713759T2 (de) 1996-04-11 2003-03-13 Mitotix Inc Assays und reaganzien zur identifizierung von fungiziden wirkstoffen und ihre verwendungen
WO1998038509A1 (en) * 1997-02-26 1998-09-03 Thyreos Corporation Drug screen targeting lipoprotein-membrane anchorage
US6303654B1 (en) * 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
WO1999055878A1 (en) * 1998-04-24 1999-11-04 Onyx Pharmaceuticals, Inc. Novel nucleic acids and polypeptides related to a farnesyl-directed cysteine carboxymethyltransferase
US20020115696A1 (en) * 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
US20050119237A1 (en) * 1999-06-18 2005-06-02 Ramot University Authority For Applied Research & Industrial Development Ltd. Non-malignant disease treatment with Ras antagonists
EP1187605A4 (de) * 1999-06-18 2004-05-26 Thyreos Corp BEHANDLUNG DER NICHT BöSARTIGEN KRANKHEITEN MIT RAS-ANTAGONISTEN
US6576261B1 (en) * 1999-08-11 2003-06-10 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
US6372793B1 (en) 1999-08-20 2002-04-16 Florida Agricultural & Mechanical University Method for treatment of a neurological disease characterized by impaired neuromodulator function
WO2004103352A1 (en) * 2003-05-23 2004-12-02 Ramot At Tel Aviv University, Ltd. Ras antagonists for treating neurodegenerative disorders
JP2007503442A (ja) * 2003-08-22 2007-02-22 ユニバーシティ オブ ヴァージニア パテント ファウンデーション ホルモン適応反応を阻止するためのmTOR遮断
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
AU2005254035B2 (en) * 2004-06-12 2011-03-24 Elizabeth Arden, Inc. Topical compositions and methods for epithelial-related conditions
ES2414861T3 (es) 2004-08-18 2013-07-23 Kadmon Corporation, Llc Uso del FTS para el tratamiento de trastornos malignos
US8278349B2 (en) * 2005-11-28 2012-10-02 Ramot At Tel-Aviv University Ltd. Cancer treatment using FTS and 2-deoxyglucose
EP1986625B1 (de) * 2006-02-10 2012-08-01 Ramot at Tel-Aviv University Ltd. Behandlung von ovarialkrebs
WO2007116396A1 (en) * 2006-04-11 2007-10-18 Ramot At Tel Aviv University Ltd. Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
US20110046223A1 (en) * 2006-06-14 2011-02-24 Ramot At Tel-Aviv University Ltd. Treatment of neurofibromatosis
ATE543492T1 (de) 2006-12-19 2012-02-15 Univ Ramot Behandlung von lungenkrebs
WO2008126094A1 (en) * 2007-04-17 2008-10-23 Ramot At Tel Aviv University Ltd. Treatment of myocarditis using fts
US7897604B2 (en) * 2008-04-07 2011-03-01 Florida Agricultural And Mechanical University Inhibitors of polyisoprenylated methylated protein methyl esterase
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2011051938A1 (en) * 2009-10-26 2011-05-05 Ramot At Tel-Aviv University Ltd. Composition for treatment of thyroid cancer with fts and analogs thereof
CN102655745B (zh) 2009-11-12 2016-01-06 西格纳姆生物科学公司 抗细菌剂用于治疗上皮相关病况的用途
US8592173B2 (en) 2011-01-25 2013-11-26 Florida Agricultural And Mechanical University Cancer diagnosis by measuring polyisoprenylated methylated protein methyl esterase activity
US8053207B1 (en) 2011-01-25 2011-11-08 Florida Agrlcultural and Mechanical University Cancer diagnosis by measuring polyisoprenylated methylated protein methyl esterase activity
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
RU2632097C2 (ru) 2011-10-07 2017-10-02 ПАЙСИЗ ТЕРАПЬЮТИКЗ ЭлЭлСи Лечение злокачественных и незлокачественных заболеваний с помощью антагонистов ras
KR20150085509A (ko) * 2012-09-21 2015-07-23 바질 리가스 염증-관련 장애, 통증 및 열, 피부 장애, 암 및 이의 전암성 질환의 치료용 조성물
US9855341B2 (en) 2014-02-19 2018-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Formulations and carrier systems including farnesylthiosalycylic moities
EP3269365A1 (de) 2016-07-14 2018-01-17 Friedrich-Alexander-Universität Erlangen-Nürnberg Kras-hemmer zur behandlung von krebs
WO2019204799A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879429A (en) 1969-04-30 1975-04-22 Hoffmann La Roche Phenyl derivatives
CH568708A5 (de) 1969-04-30 1975-11-14 Hoffmann La Roche
US3910894A (en) * 1970-05-14 1975-10-07 Du Pont Insect hormone mimics
AU2843371A (en) * 1970-05-22 1972-11-09 Ceskoslovenska Akademie Ved Novel compounds
JPS4924215A (de) 1972-07-03 1974-03-04
NL191744C (nl) * 1980-04-07 1996-06-04 Eisai Co Ltd Farmaceutisch preparaat met werking tegen epitheelletsels.
DE3862411D1 (de) * 1987-03-17 1991-05-23 Kuraray Co Verfahren zur herstellung von sulfonen.
DE3738406A1 (de) * 1987-11-12 1989-05-24 Henkel Kgaa Sebosuppressive topische zubereitungen
CA2076012A1 (en) * 1990-02-14 1991-08-15 Yasuyuki Kato Agent for inhibiting the formation of denatured ldl
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
CA2050514A1 (en) * 1990-09-14 1992-03-15 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation

Also Published As

Publication number Publication date
EP0729354A1 (de) 1996-09-04
WO1995013059A1 (en) 1995-05-18
DE69429821T2 (de) 2002-11-28
AU1396395A (en) 1995-05-29
JPH09508618A (ja) 1997-09-02
CA2176373C (en) 2009-03-24
IL107587A (en) 1998-08-16
JP3757236B2 (ja) 2006-03-22
EP0729354B1 (de) 2002-02-06
USRE39682E1 (en) 2007-06-05
CA2176373A1 (en) 1995-05-18
US5705528A (en) 1998-01-06
EP0729354A4 (de) 1996-07-15
IL107587A0 (en) 1994-02-27

Similar Documents

Publication Publication Date Title
DE69429821T2 (de) Farnesyl-derivate und diese enthaltende arzneimittel
ATE248594T1 (de) Irbesartanhaltiges arzneimittel
DE69328492T2 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
IL105221A0 (en) Cyclohexane derivatives and pharmaceutical compositions containing them
BR1100824A (pt) Composto e composição farmacêutica
IL106431A0 (en) Aminediol derivatives and pharmaceutical compositions containing the same
NO305952B1 (no) 1,5-benzodiazepinderivater, anvendelse derav og farmasoeytiske preparater
DE69124721D1 (de) Carbostyrilderivate und diese enthaltende pharmazeutische Zusammensetzungen
HU9502066D0 (en) Pyrrolidine and thiazolidine derivatives, their preparation and drugs containing same
DE69333072D1 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
DE69417897D1 (de) 2-hydroxypropandiaminderivate und diese enthaltende detergenzzubereitung
DE69320242T2 (de) Medizinische Selbstklebefolie und Arzneimittelzubereitung
EP0498268A3 (en) 5-oxo-l-proline derivatives and pharmaceutical use thereof
DE69732649D1 (de) Heteroarylsulfonamidderivate und diese enthaltende pharmazeutische zubereitungen
DE3685604T2 (de) 1,7-naphthyridinderivate und diese enthaltende arzneimittel.
DE4494713T1 (de) Arylsulfonamidderivate und diese Derivate enthaltende Arzneimittel
DE69427551D1 (de) Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
DE3481125D1 (de) Pheophorbidderivate und diese enthaltende pharmazeutische mittel.
DE59410107D1 (de) Chinoxaline und arzneimittel daraus
DK86492D0 (da) Laegemiddel
DE69622648D1 (de) Benzoxalepin-derivate, deren salze und diese enthaltende arzneimittel
DE69521347T2 (de) Ketonitrilderivate, antibaktrielle mittel und sie enthaltende arzneimittel
DE69509621D1 (de) Diarylheptanoidderivat und diese enthaltende pharmazeutische Zusammensetzung
DE69811253T2 (de) Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KRAMER - BARSKE - SCHMIDTCHEN, 81245 MUENCHEN